Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck KGaA has initiated a new Phase III study evaluating the alpha aminoamide derivative safinamide in patients with early Parkinson's disease with changes to dosing and the primary efficacy endpoint informed by the results of an earlier failed trial
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.